Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phentermine for Early Non-responders to Behavioral Weight Loss
NCT03779048Phase 4Completed
- Sponsor
- University of Pennsylvania
- Start
- Jul 2019
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of phentermine in obesity (3 arms), sponsored by University of Pennsylvania. Primary endpoints: Phase 1: Percent Weight Loss, Phase 1: Number of Participants Who Are Categorized as Early Non-responders at Randomization at Week 0 and 4 more. Started Jul 2019; status: completed.
02
Drugs
phentermine
03
Conditions
obesity
Beyond the preview
Go deeper on NCT03779048.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03779048.